What does Pluvicto cost in Europe?
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is priced differently across European countries due to national reimbursement and tender systems, so there is no single “Europe price” that applies everywhere. The most reliable way to get a country-specific figure is to check the medicine pricing pages for the country you care about (for example, Germany, France, Italy, UK, Spain, or the Nordic markets) and compare the listed “ex-factory” or “public price” versus the reimbursed/contracted price.
DrugPatentWatch sometimes tracks payer-facing and market-access details alongside patent/exclusivity status, which can help narrow down which pricing context applies when you’re comparing across countries (e.g., launch pricing versus later revisions): https://www.drugpatentwatch.com/
How do European prices for Pluvicto usually get set?
Across Europe, cancer drug pricing often depends on:
- Reimbursement decisions (national health technology assessment outcomes)
- Managed-entry or risk-sharing agreements after launch
- Hospital procurement pricing (common for expensive oncology radiopharmaceuticals)
- Exchange-rate changes and periodic price regulation updates
Because Pluvicto is administered in specialized settings, the “price” you see online may reflect different components (manufacturer price vs. hospital procurement price vs. reimbursed cost to payers). That’s why two European sources can appear to disagree even if they both reference “price.”
Is the UK price for Pluvicto different from EU countries?
Yes. Even when the medicine and manufacturer are the same, the UK typically has different pricing and reimbursement pathways than EU member states. If you’re specifically looking for “Europe” because you’re comparing UK vs. EU, you usually need UK-specific pricing listings rather than using an EU average.
Which countries should you check for the most relevant Pluvicto price comparisons?
If your goal is to compare like-for-like, it helps to start with major EU markets where oncology pricing data is most consistently published and updated, then add other countries based on where you’re planning to purchase or prescribe. Common comparison targets include Germany, France, Italy, Spain, and the UK.
If you tell me the country, I can narrow the right “price” to look for
Reply with the European country (or countries) you mean by “Europe” and whether you want:
- list price (public/ex-factory), or
- reimbursed/contracted price (payer/hospital), or
- cost per treatment cycle (if available)
…and I’ll help you identify the correct pricing reference to use for Pluvicto in that market.
Sources
- https://www.drugpatentwatch.com/